129 related articles for article (PubMed ID: 27649069)
1. A new functional IDH2 genetic variant is associated with the risk of lung cancer.
Li J; Lu J; He Y; Wu Y; Wu Y; Song X; Jiang Y; Tang M; Weng X; Yi W; Luo X; Sun L; Bode AM; Cao Y
Mol Carcinog; 2017 Mar; 56(3):1082-1087. PubMed ID: 27649069
[TBL] [Abstract][Full Text] [Related]
2. IDH2 is a novel diagnostic and prognostic serum biomarker for non-small-cell lung cancer.
Li JJ; Li R; Wang W; Zhang B; Song X; Zhang C; Gao Y; Liao Q; He Y; You S; Tan Z; Luo X; Li Y; Tang M; Weng X; Yi W; Peng S; Liu S; Tan Y; Bode AM; Cao Y
Mol Oncol; 2018 May; 12(5):602-610. PubMed ID: 29465809
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants in genes of tricarboxylic acid cycle key enzymes are associated with prognosis of patients with non-small cell lung cancer.
Guo X; Li D; Wu Y; Chen Y; Zhou X; Wang X; Huang X; Li X; Yang H; Xing J
Lung Cancer; 2015 Feb; 87(2):162-8. PubMed ID: 25576295
[TBL] [Abstract][Full Text] [Related]
4. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
[TBL] [Abstract][Full Text] [Related]
5. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
[TBL] [Abstract][Full Text] [Related]
6. Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1α in lung cancer.
Li J; He Y; Tan Z; Lu J; Li L; Song X; Shi F; Xie L; You S; Luo X; Li N; Li Y; Liu X; Tang M; Weng X; Yi W; Fan J; Zhou J; Qiang G; Qiu S; Wu W; Bode AM; Cao Y
Theranostics; 2018; 8(15):4050-4061. PubMed ID: 30128035
[TBL] [Abstract][Full Text] [Related]
7. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
8. Genomic Profiling Identifies Association of
Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
[TBL] [Abstract][Full Text] [Related]
9. IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1‑mutant tumor cells.
Zhang Y; Lv W; Li Q; Wang Q; Ru Y; Xiong X; Yan F; Pan T; Lin W; Li X
Mol Med Rep; 2019 Aug; 20(2):1893-1900. PubMed ID: 31257503
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.
Reitman ZJ; Yan H
J Natl Cancer Inst; 2010 Jul; 102(13):932-41. PubMed ID: 20513808
[TBL] [Abstract][Full Text] [Related]
11. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
[TBL] [Abstract][Full Text] [Related]
12. Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis.
Phan K; Ng W; Lu VM; McDonald KL; Fairhall J; Reddy R; Wilson P
World Neurosurg; 2018 Mar; 111():e539-e545. PubMed ID: 29288860
[TBL] [Abstract][Full Text] [Related]
13. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
[TBL] [Abstract][Full Text] [Related]
15. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.
Murugan AK; Bojdani E; Xing M
Biochem Biophys Res Commun; 2010 Mar; 393(3):555-9. PubMed ID: 20171178
[TBL] [Abstract][Full Text] [Related]
16. IDH2 mutation in gliomas including novel mutation.
Koh J; Cho H; Kim H; Kim SI; Yun S; Park CK; Lee SH; Choi SH; Park SH
Neuropathology; 2015 Jun; 35(3):236-44. PubMed ID: 25495392
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of glioma and IDH1/IDH2 mutations.
Rossetto M; Ciccarino P; Boisselier B; Labussiere M; Sanson M
Rev Neurol (Paris); 2011 Oct; 167(10):699-703. PubMed ID: 21885076
[TBL] [Abstract][Full Text] [Related]
18. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Wang P; Dong Q; Zhang C; Kuan PF; Liu Y; Jeck WR; Andersen JB; Jiang W; Savich GL; Tan TX; Auman JT; Hoskins JM; Misher AD; Moser CD; Yourstone SM; Kim JW; Cibulskis K; Getz G; Hunt HV; Thorgeirsson SS; Roberts LR; Ye D; Guan KL; Xiong Y; Qin LX; Chiang DY
Oncogene; 2013 Jun; 32(25):3091-100. PubMed ID: 22824796
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800
[TBL] [Abstract][Full Text] [Related]
20. Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group.
Nomdedéu J; Hoyos M; Carricondo M; Esteve J; Bussaglia E; Estivill C; Ribera JM; Duarte R; Salamero O; Gallardo D; Pedro C; Aventin A; Brunet S; Sierra J
Leuk Res; 2012 Aug; 36(8):990-7. PubMed ID: 22520341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]